{"article_title": "This Could Be A Monumental Year For The 340B Program", "article_keywords": ["activities", "340b", "shankar", "monumental", "program", "york", "significant", "scope", "2016", "view"], "article_url": "http://www.law360.com/articles/740725/this-could-be-a-monumental-year-for-the-340b-program", "article_text": "This Could Be A Monumental Year For The 340B Program\n\nLaw360, New York (January 3, 2016, 9:08 AM ET) -- Elizabeth S. Elson\n\n\n\nAnil Shankar During 2015, the 340B Drug Pricing Program was the focus of legal, regulatory and political activities, including the proposal of significant new \u201cmega guidance,\u201d court battles addressing the scope of the government\u2019s authority to regulate the program, an increase in audits of participating providers (covered entities) and multiple congressional hearings discussing the future of the program. These activities will continue in 2016, which is likely to be a monumental year for the program.\n\n\n\nThe 340B program provides significant discounts on the cost of...\n\nTo view the full article, register now.", "article_metadata": {"description": "Based on the events of late 2015 and the regulatory agenda for 2016, it should be a prodigious year for the 340B Drug Pricing Program, covered entities, drug manufacturers and policymakers, say Elizabeth Elson and Anil Shankar at Foley & Lardner LLP.", "apple-itunes-app": "app-id=934560389, app-argument=law360://www.law360.com/articles/740725/this-could-be-a-monumental-year-for-the-340b-program", "csrf-token": "JO/bJagiVebAd46ZrWUxLyzL0b5hvSk2RxMlP9LN+o07AUPi7TBroeT0AsfHCYsdaAuowK9rkw9XTqvCOfIpZA==", "csrf-param": "authenticity_token", "og": {"url": "http://www.law360.com/articles/740725/this-could-be-a-monumental-year-for-the-340b-program", "image": "https://www.law360.com/images/360.png", "type": "website", "title": "This Could Be A Monumental Year For The 340B Program - Law360"}, "viewport": "width=device-width, initial-scale=1.0"}, "_id": "\"57477af46914bd0286fdffed\"", "article_summary": "The 340B program provides significant discounts on the cost of...To view the full article, register now.\nThese activities will continue in 2016, which is likely to be a monumental year for the program.\nThis Could Be A Monumental Year For The 340B ProgramLaw360, New York (January 3, 2016, 9:08 AM ET) -- Elizabeth S. ElsonAnil Shankar During 2015, the 340B Drug Pricing Program was the focus of legal, regulatory and political activities, including the proposal of significant new \u201cmega guidance,\u201d court battles addressing the scope of the government\u2019s authority to regulate the program, an increase in audits of participating providers (covered entities) and multiple congressional hearings discussing the future of the program."}